Actively Recruiting
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
Led by HudsonAlpha Institute for Biotechnology · Updated on 2025-08-28
200
Participants Needed
1
Research Sites
51 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments is that they tend to be more effective when started early. Previous studies have shown that multimodal lifestyle interventions can significantly delay the onset of Alzheimer's dementia in individuals with high risk for Alzheimer's or with Mild Cognitive Impairment (MCI). These interventions may be less effective when initiated after dementia has already been diagnosed or is more advanced. This study has two primary goals. The first goal is to assess attitudes around dementia risk for participants throughout the study as they learn of their personalized risk and possible lifestyle factors that may modify that risk. The second goal is to serve as a logistical pilot for the implementation of data collection and processing and multimodal lifestyle intervention to reduce the risk factors of dementia in individuals without current cognitive impairment but who are at high risk of progression to dementia. Secondary goals of this study include better defining what factors contribute the most risk to dementia and identifying sub-types of dementia defined by different genetic and molecular risk factors.
CONDITIONS
Official Title
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 65 to 75 years old at enrollment with at least one first-degree relative who has or had any type of dementia
- Montreal Cognitive Assessment (MoCA) score greater than 24 at initial enrollment
- Able and willing to understand and sign the informed consent document
- Able and willing to perform required physical performance tests
- Able and willing to provide the study's minimum biological samples
- Able and willing to complete the study's required procedures
- Able and willing to complete surveys, cognitive assessments, and questionnaires in English only
- Has or has ready access to a PC, tablet, or smartphone with internet for study procedures
You will not qualify if you...
- Diagnosis of any cognitive impairment, including Alzheimer's disease, mild cognitive impairment, or other dementia
- MoCA score less than 25 at initial enrollment
- Self-reported pregnancy
- Children under 19 years old
- Not fluent in written and spoken English
- Self-reported chronic or end-stage disease interfering with study participation
- Hospitalization for any reason in the past 3 months
- Severe hearing or visual impairment interfering with study measures
- Any other vulnerable subject at enrollment as specified
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Smith Family Clinic for Genomic Medicine
Huntsville, Alabama, United States, 35806
Actively Recruiting
Research Team
J
Jesse N Cochran, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here